

General Assignment

Between

VAN HELDEN, Paula Maria Wilhelmina (hereinafter referred to as "Assignor")

AND

Lava Therapeutics N.V., having its place of business at Yalelaan 62, 3584CM, Utrecht, The Netherlands (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/52 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)");
and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.




The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.



VAN HELDEN, Paula Maria Wilhelmina



Authorized Signatory
Lava Therapeutics N.V.

Amy Garabedian, General Counsel

Signature Date: 03 DEC 2024

DD Month YYYY

Signature Date: 03 - DEC - 2024

DD Month YYYY

General Assignment

Between

VAN DER VLIET, Johannes Jelle (hereinafter referred to as "Assignor")

AND

Lava Therapeutics N.V., having its place of business at Yalelaan 62, 3584CM, Utrecht, The Netherlands (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/ δ 2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.

(hereinafter referred to as "Patent Application(s)");
and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.



.....
VAN DER VLIET, Johannes Jelle



.....
Authorized Signatory
Lava Therapeutics N.V.
Amy Garabedian, General Counsel

Signature Date: 03-dec-2024 .

DD Month YYYY

Signature Date: 03-DEC-2024

DD Month YYYY

General Assignment

Between

ROOVERS, Robertus Cornelis (hereinafter referred to as "Assignor")

AND

Lava Therapeutics N.V., having its place of business at Yalelaan 60, 3584CM, Utrecht, The Netherlands (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/52 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.

(hereinafter referred to as "Patent Application(s)");
and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.


IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.



ROOVERS, Robertus Cornelis

Signature Date:

02-12-2024



Authorized Signatory
Lava Therapeutics N.V.

Amy Garabedian, General Counsel

Signature Date:

02-12-2024

General Assignment

Between

KALLAL, Lorena A

(hereinafter referred to as "Assignor")

AND

Janssen Research and Development, LLC, having its place of business at 920 US Route 202,
PO Box 300, Raritan NJ 08869, USA.
(hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/52 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)");
and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.



KALLAL, Lorena A



Jim Ghedira

Authorized Signatory

Janssen Research and Development, LLC

08.02-2024

Signature Date:

DD Month YYYY

Signature Date:

13 February 2024

DD Month YYYY

General Assignment

WHEREAS, **Janssen Research and Development, LLC**, having its place of business at 920 US Route 202, PO Box 300, Raritan NJ 08869, USA.
(hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"CD33 ANTIBODIES, CD33/52 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

hereinafter referred to as "Invention",
for which on the 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)"),

WHEREAS, **Janssen Biotech, Inc.**, having its place of business at 800/850 Ridgeview Drive, Horsham, PA, 19044, United States of America, (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority of the above mentioned Patent Application(s) for the Invention both domestic and foreign; and

WHEREAS, the conditions under which said Invention was made are such that the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.


NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

And for the purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that the assignment or confirmation of the assignment to the Assignee of any right, title and interest, in and to all said Inventions disclosed in said Patent Application(s) and in and to said Patent Application(s), and all foreign equivalents thereof, can be effected via a direct assignment by the inventor(s) of said Inventions to the Assignee without requiring the explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.


For **Janssen Research and Development, LLC**


.....
Rim Ghadira
Authorized Signatory
Janssen Research and Development, LLC
Signature Date:

DD Month YYYY

13 February 2024

For **Janssen Biotech, Inc**


.....
Lisbeth Veenstra
Authorized Signatory
Janssen Biotech, Inc
Signature Date:

DD Month YYYY

13/02/2024

General Assignment

Between

MERAT, Sabrina Julia Louisa (hereinafter referred to as "Assignor")

AND

Lava Therapeutics N.V., having its place of business at Yalelaan 62, 3584CM, Utrecht, The Netherlands (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/52 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.

(hereinafter referred to as "Patent Application(s)");

and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.


NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.


The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.



MERAT, Sabrina Julia Louisa



Authorized Signatory

Lava Therapeutics N.V.

Amy Garabedian, General Counsel

Signature Date: 05-dec-2024

DD Month YYYY

Signature Date: 05 Dec 2024

DD Month YYYY

General Assignment

Between

PARREN, Paul Willem Henri Ida (hereinafter referred to as "Assignor")

AND

Lava Therapeutics N.V., having its place of business at Yalelaan 60, 3584CM, Utrecht, The Netherlands (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/52 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)");
and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.



NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.


.....
PARREN, Paul Willem Henri Ida
.....
Authorized Signatory
Lava Therapeutics N.V.
Amy Garabedian, General Counsel

Signature Date:

02-12-2024
DD Month YYYY

Signature Date: 03-DEC-2024

DD Month YYYY

General Assignment

Between

ELASHKAR, Sara Mohamed A

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium.

(hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.

(hereinafter referred to as "Patent Application(s)");

and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.



NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.


.....
ELASHKAR, Sara Mohamed A

.....**FILIP VERBERCKMOES**.....

Authorized Signatory
Janssen Pharmaceutica NV

Signature Date:

22/01/2024

Signature Date: 23 January 2023

DD Month YYYY

General Assignment

WHEREAS, **Janssen Pharmaceutica NV**, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium.
(hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

hereinafter referred to as "Invention",
for which on the 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)"),

WHEREAS, **Janssen Biotech, Inc.**, having its place of business at 800/850 Ridgeview Drive, Horsham, PA, 19044, United States of America, (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority of the above mentioned Patent Application(s) for the Invention both domestic and foreign; and

WHEREAS, the conditions under which said Invention was made are such that the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.


NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

And for the purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that the assignment or confirmation of the assignment to the Assignee of any right, title and interest, in and to all said Inventions disclosed in said Patent Application(s) and in and to said Patent Application(s), and all foreign equivalents thereof, can be effected via a direct assignment by the inventor(s) of said Inventions to the Assignee without requiring the explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from 8 December 2023.


IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For **Janssen Pharmaceutica NV**


.....**FILIP VERBERCKMOES**.....

Authorized Signatory
Janssen Pharmaceutica NV
Signature Date: 23 January 2023

For **Janssen Biotech, Inc**


.....

Authorized Signatory *Lisbeth Vercaut*
Janssen Biotech, Inc
Signature Date: 13/02/2024

DD Month YYYY

DD Month YYYY JBI6837

General Assignment

Between

PHILIPPAR, Ulrike

(hereinafter referred to as "Assignor")

AND

Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium.

(hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.

(hereinafter referred to as "Patent Application(s)");

and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

Ulrike PHILIPPAR

Electronically signed by: Ulrike
PHILIPPAR
Date: Dec 2, 2024 18:07 GMT+1

.....
PHILIPPAR, Ulrike

Signature Date:

Dec 2, 2024

Electronically signed by:
FILIP VERBERCKMOES
Date: Dec 3, 2024 09:49
GMT+1

FILIP VERBERCKMOES

.....
Authorized Signatory
Janssen Pharmaceutica NV

Signature Date:

Dec 3, 2024

General assignment for JBI6837 PHILIPPAR - request for your signature

Final Audit Report

2024-12-03

Created:	2024-11-29
By:	Sarah Van Oeckel (SVanOeck@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAA7sELQPtAWfUzFO5891BUj6r5CzwhXv9P

"General assignment for JBI6837 PHILIPPAR - request for your signature" History

-  Document created by Sarah Van Oeckel (SVanOeck@its.jnj.com)
2024-11-29 - 10:04:56 AM GMT- IP address: 165.225.13.1
-  Document emailed to Ulrike PHILIPPAR (uphilipp@its.jnj.com) for signature
2024-11-29 - 10:12:00 AM GMT
-  Email viewed by Ulrike PHILIPPAR (uphilipp@its.jnj.com)
2024-12-02 - 5:06:48 PM GMT- IP address: 104.47.74.126
-  Document e-signed by Ulrike PHILIPPAR (uphilipp@its.jnj.com)
Signature Date: 2024-12-02 - 5:07:18 PM GMT - Time Source: server- IP address: 165.225.13.2
-  Document emailed to FILIP VERBERCKMOES (fverberc@its.jnj.com) for signature
2024-12-02 - 5:07:21 PM GMT
-  Email viewed by FILIP VERBERCKMOES (fverberc@its.jnj.com)
2024-12-02 - 5:37:16 PM GMT- IP address: 84.197.29.242
-  Document e-signed by FILIP VERBERCKMOES (fverberc@its.jnj.com)
Signature Date: 2024-12-03 - 8:49:50 AM GMT - Time Source: server- IP address: 165.225.12.224
-  Agreement completed.
2024-12-03 - 8:49:50 AM GMT

General Assignment

Between

DOONAN, Patrick John

(hereinafter referred to as "Assignor")

AND

Janssen Research and Development, LLC, having its place of business at 920 US Route 202,
PO Box 300, Raritan NJ 08869, USA.

(hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.

(hereinafter referred to as "Patent Application(s)");

and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.



Electronically signed by:
Patrick Doonan
Date: Dec 2, 2024 06:35
EST

DOONAN, Patrick John



Electronically signed by:
Rim Ghedira
Date: Dec 3, 2024 07:40
GMT+1

Authorized Signatory
Janssen Research and Development, LLC

Signature Date:

Dec 2, 2024

Signature Date:

Dec 3, 2024

General assignment JBI6837 DOONAN

Final Audit Report

2024-12-03

Created:	2024-11-29
By:	Sarah Van Oeckel (SVanOeck@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAABtkS98KZb5hDNGVGvN0zqBIAyl_gVsh

"General assignment JBI6837 DOONAN" History

-  Document created by Sarah Van Oeckel (SVanOeck@its.jnj.com)
2024-11-29 - 10:35:48 AM GMT- IP address: 165.225.13.1
-  Document emailed to patrickdoonan@gmail.com for signature
2024-11-29 - 10:36:28 AM GMT
-  Email viewed by patrickdoonan@gmail.com
2024-12-02 - 11:33:37 AM GMT- IP address: 108.16.19.154
-  Signer patrickdoonan@gmail.com entered name at signing as Patrick Doonan
2024-12-02 - 11:35:15 AM GMT- IP address: 108.16.19.154
-  Document e-signed by Patrick Doonan (patrickdoonan@gmail.com)
Signature Date: 2024-12-02 - 11:35:17 AM GMT - Time Source: server- IP address: 108.16.19.154
-  Document emailed to Rim Ghedira (rghedira@its.jnj.com) for signature
2024-12-02 - 11:35:19 AM GMT
-  Email viewed by Rim Ghedira (rghedira@its.jnj.com)
2024-12-03 - 6:39:59 AM GMT- IP address: 104.47.73.126
-  Document e-signed by Rim Ghedira (rghedira@its.jnj.com)
Signature Date: 2024-12-03 - 6:40:15 AM GMT - Time Source: server- IP address: 165.225.12.230
-  Agreement completed.
2024-12-03 - 6:40:15 AM GMT

General Assignment

Between

JACOBS, Steven A

(hereinafter referred to as "Assignor")

AND

Janssen Research and Development, LLC, having its place of business at 920 US Route 202,
PO Box 300, Raritan NJ 08869, USA.

(hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee.

The Assignor is (co-)inventor of the Invention, for which on 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.

(hereinafter referred to as "Patent Application(s)");

and

WHEREAS, the conditions under which said Invention was made are such that as employee of Assignee the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalent applications thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this general assignment, and the Assignor has not executed and will not execute any agreement in conflict with this general assignment without consent of Assignee.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution and enforcement of any application(s) for the Invention, including all provisionals, substitutions, divisions, and continuations thereof, or for Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any declaration and power of attorney that may be necessary in the prosecution and enforcement of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

Electronically signed by:
STEVEN JACOBS
Date: Dec 2, 2024 08:40
EST.....
JACOBS, Steven A

Electronically signed by:
Rim Ghedira
Date: Dec 3, 2024 07:37
GMT+1.....

Authorized Signatory
Janssen Research and Development, LLC

Signature Date:

Dec 2, 2024

Signature Date:

Dec 3, 2024

JB16837 GA JACOBS

Final Audit Report

2024-12-03

Created:	2024-11-29
By:	Sarah Van Oeckel (SVanOeck@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAsKksBneNvsteoDdJ-HZ-wTD3E6c8GX34

"JB16837 GA JACOBS" History

-  Document created by Sarah Van Oeckel (SVanOeck@its.jnj.com)
2024-11-29 - 11:02:59 AM GMT- IP address: 165.225.13.1
-  Document emailed to STEVEN JACOBS (sjacobs9@its.jnj.com) for signature
2024-11-29 - 11:03:32 AM GMT
-  Email viewed by STEVEN JACOBS (sjacobs9@its.jnj.com)
2024-12-02 - 1:39:49 PM GMT- IP address: 104.47.74.126
-  Document e-signed by STEVEN JACOBS (sjacobs9@its.jnj.com)
Signature Date: 2024-12-02 - 1:40:14 PM GMT - Time Source: server- IP address: 170.85.71.15
-  Document emailed to Rim Ghedira (rghedira@its.jnj.com) for signature
2024-12-02 - 1:40:16 PM GMT
-  Email viewed by Rim Ghedira (rghedira@its.jnj.com)
2024-12-03 - 6:36:29 AM GMT- IP address: 104.47.74.126
-  Document e-signed by Rim Ghedira (rghedira@its.jnj.com)
Signature Date: 2024-12-03 - 6:37:36 AM GMT - Time Source: server- IP address: 165.225.12.230
-  Agreement completed.
2024-12-03 - 6:37:36 AM GMT

General Assignment

WHEREAS, **Janssen Pharmaceutica NV**, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium.
(hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

hereinafter referred to as "Invention",
for which on the 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)"),

WHEREAS, **Janssen Biotech, Inc.**, having its place of business at 800/850 Ridgeview Drive, Horsham, PA, 19044, United States of America, (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority of the above mentioned Patent Application(s) for the Invention both domestic and foreign; and

WHEREAS, the conditions under which said Invention was made are such that the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.


NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

And for the purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that the assignment or confirmation of the assignment to the Assignee of any right, title and interest, in and to all said Inventions disclosed in said Patent Application(s) and in and to said Patent Application(s), and all foreign equivalents thereof, can be effected via a direct assignment by the inventor(s) of said Inventions to the Assignee without requiring the explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For **Janssen Pharmaceutica NV**



Filip Verberckmoes

Authorized Signatory

Janssen Pharmaceutica NV

Signature Date:

DD Month YYYY

3 December 2024

For **Janssen Biotech, Inc**



Liesbeth Vervoort

Authorized Signatory

Janssen Biotech, Inc

Signature Date:

DD Month YYYY

General Assignment

WHEREAS, **Janssen Research and Development, LLC**, having its place of business at 920 US Route 202, PO Box 300, Raritan NJ 08869, USA.
(hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"CD33 ANTIBODIES, CD33/52 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

hereinafter referred to as "Invention",
for which on the 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)"),

WHEREAS, **Janssen Biotech, Inc.**, having its place of business at 800/850 Ridgeview Drive, Horsham, PA, 19044, United States of America, (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority of the above mentioned Patent Application(s) for the Invention both domestic and foreign; and

WHEREAS, the conditions under which said Invention was made are such that the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

And for the purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that the assignment or confirmation of the assignment to the Assignee of any right, title and interest, in and to all said Inventions disclosed in said Patent Application(s) and in and to said Patent Application(s), and all foreign equivalents thereof, can be effected via a direct assignment by the inventor(s) of said Inventions to the Assignee without requiring the explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For **Janssen Research and Development, LLC**



.....
Rim Ghedira

Authorized Signatory
Janssen Research and Development, LLC
Signature Date:

DD Month YYYY

03 Dec. 2024

For **Janssen Biotech, Inc**


.....
Liesbeth Vervoort

Authorized Signatory
Janssen Biotech, Inc
Signature Date:

DD Month YYYY

General Assignment

WHEREAS, **Lava Therapeutics N.V.**, having its place of business at Yalelaan 62, 3584CM, Utrecht, The Netherlands (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

hereinafter referred to as "Invention",
for which on the 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)"),

WHEREAS, **Janssen Biotech, Inc.**, having its place of business at 800/850 Ridgeview Drive, Horsham, PA, 19044, United States of America, (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority of the above mentioned Patent Application(s) for the Invention both domestic and foreign; and

WHEREAS, the conditions under which said Invention was made are such that the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.


NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

And for the purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that the assignment or confirmation of the assignment to the Assignee of any right, title and interest, in and to all said Inventions disclosed in said Patent Application(s) and in and to said Patent Application(s), and all foreign equivalents thereof, can be effected via a direct assignment by the inventor(s) of said Inventions to the Assignee without requiring the explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For **Lava Therapeutics N.V.**




Name: **Amy Garabedian**

Title: General Counsel

Signature Date: **5 December 2024**

For **Janssen Biotech, Inc**



Authorized Signatory

Signature Date:

DD Month YYYY

General Assignment

WHEREAS, **Lava Therapeutics N.V.**, having its place of business at Yalelaan 62, 3584CM, Utrecht, The Netherlands (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"CD33 ANTIBODIES, CD33/δ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF"

hereinafter referred to as "Invention",
for which on the 8 December 2023, USA application no. 63/608030 was filed at the United States Patent and Trademark Office.
(hereinafter referred to as "Patent Application(s)),

WHEREAS, **Janssen Biotech, Inc.**, having its place of business at 800/850 Ridgeview Drive, Horsham, PA, 19044, United States of America, (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority of the above mentioned Patent Application(s) for the Invention both domestic and foreign; and

WHEREAS, the conditions under which said Invention was made are such that the Assignor is desirous of assigning and transferring to Assignee the entire right, title and interest to said Invention, including the right to claim priority of the Patent Application(s), both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged by the Assignee, the Assignor for the avoidance of doubt assigns and transfers or has assigned and has transferred to the Assignee its entire right, title and interest, including the right to claim priority of the Patent Application(s) under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes, for the Invention, in and to said Invention, which is disclosed in the Patent Application(s), and in and to said Patent Application(s), and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, reissues and limitations thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this general assignment had not been made.

And for the purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that the assignment or confirmation of the assignment to the Assignee of any right, title and interest, in and to all said Inventions disclosed in said Patent Application(s) and in and to said Patent Application(s), and all foreign equivalents thereof, can be effected via a direct assignment by the inventor(s) of said Inventions to the Assignee without requiring the explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from 8 December 2023.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For **Lava Therapeutics N.V.**

For **Janssen Biotech, Inc**

.....
Name:

Title:

Signature Date:

DD Month YYYY

.....
Liesbeth Vervoort

Authorized Signatory

Signature Date:

DD Month YYYY